Skip to main content

Intracavernosal Injections (ICI)

Intracavernosal injection (ICI) of vasoactive agents into the corpus cavernosum produces erection independent of neurogenic stimulation. It is an option for men with contraindications to PDE5 inhibitors, men who prefer not to take an oral drug and men in whom PDE5 inhibitors are ineffective, including men after prostatectomy.[1] Alprostadil (prostaglandin E1) monotherapy and TriMix (papaverine, phentolamine, alprostadil) are the most commonly used formulations. Alprostadil is the only agent FDA-approved for ICI in the US; combinations are compounded.[1]

For drug formulations, see Intracavernosal Injection Agents.

Indications​

IndicationWhy ICI is useful
PDE5i failure or contraindicationDirect corporal smooth-muscle pharmacology bypasses impaired NO signaling[1]
Post-prostatectomy EDActs directly on the corpora, so it does not depend on intact cavernous nerve signaling[1]
ED with diabetes or prior pelvic radiationIn a tertiary series, response was lower in these groups; 89% of all TriMix users could have intercourse[3]
Diagnostic penile duplex Doppler ultrasoundProduces pharmacologic erection for arterial inflow and veno-occlusive assessment
Prolonged erection after ICIIntracavernosal phenylephrine is the rescue drug and not an ED induction agent[2]

Agents & Formulations​

FormulationComponentsPractical role
AlprostadilPGE1FDA-approved monotherapy; penile pain with erection can limit use[1]
BiMixPapaverine + phentolamineCompounded combination
TriMixAlprostadil + papaverine + phentolamineMost patients in a 1,412-man tertiary cohort used it; 89% of TriMix users could have intercourse[3]
QuadMixTriMix + atropineUsed after failure of three-drug combinations in a stepped-care program[1]
PhenylephrineAlpha-1 agonistPriapism / prolonged-erection rescue, dosed and monitored separately[2]

Combination therapy was developed to use lower doses of each component, aiming to improve efficacy and reduce adverse effects.[1] A 2025 systematic review of 12 studies (five randomized trials) found no consistent adverse-effect advantage for combination ICI over monotherapy; priapism was more frequent with combinations when all studies were pooled (OR 1.84, 95% CI 1.03–3.20), but the difference was not significant in the randomized trials alone, and fibrosis comparisons were sparse.[6] No combination is FDA-approved, concentrations vary widely, and some components (alprostadil) have limited shelf life.[1] The AUA guideline describes 30 mg papaverine, 10 µg alprostadil and 1 mg phentolamine per mL, starting at 0.1–0.5 mL for that mixture.[1] Compounded concentrations vary widely; select and titrate the prescribed mixture in office.[1]

Technique Overview​

  1. Before alprostadil use, screen for labeled contraindications: hypersensitivity; sickle cell disease or trait, leukemia or multiple myeloma; penile deformity, cavernosal fibrosis or Peyronie’s disease; and a penile implant.[4] The EAU 2026 guideline also lists bleeding disorders as a contraindication to intracavernosal alprostadil.[5] Assess whether cardiovascular status permits sexual activity. Avoid Caverject in patients with known cavernosal venous leakage because systemic alprostadil exposure can cause hypotension.[4] Perform the first injection in an office with the expertise and facilities to manage ischemic priapism; titrate the dose and confirm complete detumescence before discharge.[2][4]
  2. Use the specified device and needle for the formulation. For Caverject, use a ½-inch, 29- or 30-gauge needle. Stretch the penis lengthwise along the thigh and inject into the right or left lateral corpus cavernosum in the proximal third, inserting the needle perpendicular to the long dorsolateral penile axis; avoid visible veins and do not bend or straighten the needle.[4]
  3. Avoid the dorsal neurovascular bundle and ventral urethra.
  4. Compress the puncture site with an alcohol swab or sterile gauze for five minutes or until bleeding stops, especially in anticoagulated patients.[4]
  5. Alternate sides and injection sites with each dose. Document any pre-existing fibrosis, plaque or deformity before starting, and monitor regularly for progression.[1] Stop alprostadil injection if penile angulation or cavernosal fibrosis develops; the Edex label also specifies stopping for Peyronie’s disease.[4]
  6. Limit frequency to no more than 3 injections per week with at least 24 hours between injections, as in alprostadil labeling.[4]
  7. Give written priapism instructions. Patients who receive ICI teaching or an in-office test are told to return to the office or emergency department for an erection lasting more than 4 hours .[2] The AUA ED guideline describes commonly used self-measures (attempting ejaculation, oral pseudoephedrine, ice) for which no evidence was retrieved, and advises presenting within 2–4 hours of injection if a painful, non-bendable erection persists.[1] AUA/SMSNA permits clinician-selected conservative measures for prolonged erections of 1–4 hours, but these must not delay treatment of a fully rigid erection beyond four hours. Pain alone does not determine the need for intervention. When a post-ICI erection of four hours or less requires treatment, intracavernosal phenylephrine is the initial option ; it is also advised when conservative management fails .[2] An erection persisting beyond four hours requires evaluation for ischemic priapism; if confirmed, promptly aspirate and give intracavernosal phenylephrine, with or without irrigation , and monitor blood pressure and heart rate .[7][2]

Outcomes & Evidence​

Persistence is the limiting outcome. The AUA ED guideline advises informing men with ED of ICI as a treatment option , does not make oral-drug failure a prerequisite, and advises an in-office injection test before home self-injection .[1] The 2026 EAU guideline recommends ICI as an alternative first-line therapy for well-informed patients or as second-line therapy .[5] In the AUA guideline's ICI evidence review, more than 90% of study arms came from observational designs.[1] In a tertiary-center series of 1,412 men (2002–2006 enrollment), 89% of TriMix users could have intercourse; priapism was recorded in 0.5% of men with complete study data.[3] Discontinuation was substantial by 3 years, in part because some men after prostatectomy recovered natural or PDE5i-assisted erections.[3] The EAU guideline cites dropout rates of 41–68%, mostly within the first two to three months.[5] Across studies the guideline reports the lowest mean priapism rate (1.8%) with single-agent alprostadil, though prolonged or painful erections occurred in a mean 6.3% of those studies.[1]

The complications to actively prevent are:

  • prolonged erection or ischemic priapism,
  • penile pain, especially with alprostadil,
  • corporal fibrosis / curvature,
  • hematoma, especially with anticoagulation,
  • dropout from anxiety, cost, or inadequate coaching.

Education before the first home injection, partner involvement when appropriate and early follow-up are practical measures to limit dropout; the AUA guideline notes that the office visit builds confidence with the technique and supports adherence.[1] The Caverject label advises review every three months or as clinically appropriate; Edex recommends office review every three months to assess efficacy, safety and dose.[4]

References​

1. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004

2. Bivalacqua TJ, Allen BK, Brock GB, et al. "The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline." J Urol. 2022;208(1):43-52. doi:10.1097/JU.0000000000002767. The Diagnosis and Management of Priapism: an AUA/SMSNA Guideline (2022), unified full guideline.

3. Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. "A review of outcomes of an intracavernosal injection therapy programme." BJU Int. 2012;110(11 Pt C):1787-1791. doi:10.1111/j.1464-410X.2012.11080.x

4. EDEX (alprostadil) and CAVERJECT (alprostadil) prescribing information. DailyMed.

5. European Association of Urology. "EAU Guidelines on Sexual and Reproductive Health: Management of Erectile Dysfunction." Limited update 2026, section 5.6.12. Official guideline.

6. Lima AS, Villela BC, Pustilnik HN, et al. "Comparison of adverse effects of combined and isolated substances in Intracavernosal injection: a systematic review and meta-analysis." J Sex Med. 2025;22(9):1579-1591. doi:10.1093/jsxmed/qdaf172

7. Bivalacqua TJ, Allen BK, Brock G, et al. "Acute Ischemic Priapism: An AUA/SMSNA Guideline." J Urol. 2021;206(5):1114-1121. doi:10.1097/JU.0000000000002236